

Jan Bornschein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1760067/publications.pdf>

Version: 2024-02-01

93
papers

4,825
citations

94269

37
h-index

102304

66
g-index

112
all docs

112
docs citations

112
times ranked

6667
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors. <i>Digestive Diseases</i> , 2009, 27, 80-92.	0.8	406
2	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. <i>Nature Genetics</i> , 2016, 48, 1131-1141.	9.4	332
3	Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. <i>Nature Genetics</i> , 2014, 46, 837-843.	9.4	302
4	Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. <i>Nature Genetics</i> , 2015, 47, 1038-1046.	9.4	262
5	Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case-Control Study. <i>PLoS Medicine</i> , 2015, 12, e1001780.	3.9	212
6	Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 333-344.	6.3	143
7	The fight against gastric cancer – the IARC Working Group report. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1107-1114.	1.0	135
8	Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. <i>BMC Gastroenterology</i> , 2014, 14, 117.	0.8	101
9	Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1816-1828.	0.1	88
10	H. pylori Infection Is a Key Risk Factor for Proximal Gastric Cancer. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3124-3131.	1.1	86
11	S3-Guideline –Helicobacter pylori and gastroduodenal ulcer disease– of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-Registration-no. 021 / 001. <i>Zeitschrift Fur Gastroenterologie</i> . 2009. 47, 1230-1263.	0.2	78
12	Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1257-1260.	0.8	71
13	Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 16245.	1.4	68
14	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. <i>Gastroenterology</i> , 2018, 155, 1720-1728.e4.	0.6	67
15	Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. <i>BMC Medical Genetics</i> , 2011, 12, 112.	2.1	65
16	Serological assessment of gastric mucosal atrophy in gastric cancer. <i>BMC Gastroenterology</i> , 2012, 12, 10.	0.8	65
17	Helicobacter pylori. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 608-614.	1.0	59
18	Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. <i>Gastroenterology</i> , 2020, 158, 1682-1697.e1.	0.6	58

#	ARTICLE	IF	CITATIONS
19	Evolution of the Diffuse Neuroendocrine System – Clear Cells and Cloudy Origins. <i>Neuroendocrinology</i> , 2006, 84, 69-82.	1.2	54
20	<i>Helicobacter pylori</i> but not gastrin is associated with the development of colonic neoplasms. <i>International Journal of Cancer</i> , 2014, 135, 1127-1131.	2.3	53
21	Clinical relevance of <i>Helicobacter pylori</i> vacA and cagA genotypes in gastric carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1003-1015.	1.0	51
22	Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2016, 115, 403-410.	2.9	49
23	Gastric Cancer: Clinical Aspects, Epidemiology and Molecular Background. <i>Helicobacter</i> , 2011, 16, 45-52.	1.6	48
24	Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. <i>Liver Cancer</i> , 2012, 1, 257-266.	4.2	48
25	Chronic gastritis – An update. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1031-1042.	1.0	48
26	Differential expression of microRNAs in preneoplastic gastric mucosa. <i>Scientific Reports</i> , 2015, 5, 8270.	1.6	48
27	HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. <i>Human Pathology</i> , 2015, 46, 665-672.	1.1	47
28	Implementation of gastric cancer screening – The global experience. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1093-1106.	1.0	46
29	Octreotide LAR: safety and tolerability issues. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 755-768.	1.0	45
30	Gastric MALT lymphoma – Update on diagnosis and treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1069-1077.	1.0	45
31	Gastric carcinogenesis. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 729-742.	0.8	41
32	<i>Helicobacter pylori</i> and Gastric Cancer. <i>Digestive Diseases</i> , 2014, 32, 249-264.	0.8	41
33	From Gastric Inflammation to Gastric Cancer. <i>Digestive Diseases</i> , 2010, 28, 609-614.	0.8	40
34	The stomach-brain axis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 967-979.	1.0	40
35	The gastrointestinal microbiome – Functional interference between stomach and intestine. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 995-1002.	1.0	39
36	Management of immune related adverse events induced by immune checkpoint inhibition. <i>Cancer Letters</i> , 2019, 456, 80-87.	3.2	36

#	ARTICLE	IF	CITATIONS
37	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. <i>Oncotarget</i> , 2014, 5, 7162-7171.	0.8	35
38	Individual risk stratification of gastric cancer: Evolving concepts and their impact on clinical practice. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1043-1053.	1.0	35
39	Clinical Characteristics and Time Trends in Etiology of Hepatocellular Cancer in Germany. <i>Digestion</i> , 2013, 87, 147-159.	1.2	34
40	Expression of aurora kinase A correlates with the Wnt modulator RACGAP 1 in gastric cancer. <i>Cancer Medicine</i> , 2016, 5, 516-526.	1.3	34
41	Gastric acid secretion: Changes during a century. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 953-965.	1.0	32
42	A Frequent Toll-Like Receptor 1 Gene Polymorphism Affects NK- and T-cell IFN γ Production and is Associated with <i>Helicobacter pylori</i> -induced Gastric Disease. <i>Helicobacter</i> , 2013, 18, 13-21.	1.6	31
43	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 239-249.	0.9	31
44	The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment: Chance or Curse?. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 857-874.	2.3	30
45	Role of <i>Helicobacter pylori</i> infection in gastric cancer pathogenesis: A chance for prevention. <i>Journal of Digestive Diseases</i> , 2010, 11, 2-11.	0.7	28
46	A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. <i>Genome Research</i> , 2017, 27, 902-912.	2.4	27
47	<i>Helicobacter pylori</i> : Gastric Cancer and Extragastric Intestinal Malignancies. <i>Helicobacter</i> , 2012, 17, 30-35.	1.6	26
48	Molecular diagnostics in gastric cancer. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 312.	3.0	25
49	EGF and BMPs Govern Differentiation and Patterning in Human Gastric Glands. <i>Gastroenterology</i> , 2021, 161, 623-636.e16.	0.6	25
50	Functional and Topological Properties in Hepatocellular Carcinoma Transcriptome. <i>PLoS ONE</i> , 2012, 7, e35510.	1.1	24
51	Pharmacological and alimentary alteration of the gastric barrier. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 981-994.	1.0	23
52	Guidelines for treatment of <i>Helicobacter pylori</i> in the East and West. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 581-588.	2.0	21
53	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. <i>Scientific Reports</i> , 2016, 6, 32417.	1.6	20
54	Hepatocellular Carcinoma and Liver Cirrhosis: Assessment of the Liver Function after Yttrium-90 Radioembolization with Resin Microspheres or after CT-Guided High-Dose-Rate Brachytherapy. <i>Digestive Diseases</i> , 2009, 27, 189-199.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 492-500.	0.8	18
56	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , 2019, 68, 1918-1927.	6.1	18
57	Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis. <i>Digestion</i> , 2011, 83, 275-282.	1.2	17
58	Dysregulation of CDX1, CDX2 and SOX2 in patients with gastric cancer also affects the non-malignant mucosa. <i>Journal of Clinical Pathology</i> , 2013, 66, 819-822.	1.0	17
59	MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression. <i>Diagnostic Pathology</i> , 2015, 10, 212.	0.9	17
60	Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. <i>International Journal of Cancer</i> , 2019, 145, 3389-3401.	2.3	17
61	Interleukin 1 beta (IL1B) gene polymorphisms are not associated with gastric carcinogenesis in Germany. <i>Anticancer Research</i> , 2010, 30, 505-11.	0.5	17
62	<i>Helicobacter pylori</i> and Clinical Aspects of Gastric Cancer. <i>Helicobacter</i> , 2009, 14, 41-45.	1.6	16
63	Clinical Aspects of Gastric Cancer and <i>Helicobacter pylori</i> – Screening, Prevention, and Treatment. <i>Helicobacter</i> , 2010, 15, 40-45.	1.6	16
64	Combined Gastric and Colorectal Cancer Screening – A New Strategy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3854.	1.8	16
65	S2k-Guideline <i>Helicobacter pylori</i> and gastroduodenal ulcer disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 167-206.	0.2	13
66	From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. <i>Histology and Histopathology</i> , 2016, 31, 25-32.	0.5	13
67	The combined presence of H pylori infection and gastro-oesophageal reflux disease leads to an up-regulation of CDX2 gene expression in antrum and cardia. <i>Journal of Clinical Pathology</i> , 2009, 62, 254-259.	1.0	11
68	Regulation of apoptosis is impaired in atrophic gastritis associated with gastric cancer. <i>BMC Gastroenterology</i> , 2017, 17, 84.	0.8	11
69	The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract. <i>Digestive Diseases</i> , 2019, 37, 381-393.	0.8	8
70	The complexity of cancer origins at the gastro-oesophageal junction. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101729.	1.0	7
71	Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Journal of Nuclear Medicine</i> , 2016, 57, 180-185.	2.8	6
72	Cost-effectiveness modelling of use of urea breath test for the management of <i>Helicobacter pylori</i> -related dyspepsia and peptic ulcer in the UK. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000685.	1.1	6

#	ARTICLE	IF	CITATIONS
73	Helicobacter pylori induced gastric carcinogenesis - The best molecular model we have?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 50-51, 101743.	1.0	5
74	COVID-19: Don't Neglect the Gastrointestinal Tract!. Digestive Diseases, 2020, 38, 259-260.	0.8	4
75	Molecular aspects in the diagnosis of gastric cancer. Expert Opinion on Medical Diagnostics, 2009, 3, 585-596.	1.6	3
76	The global challenge of a healthy stomach. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 949-951.	1.0	3
77	Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study. Journal of Clinical Pathology, 2019, 72, 825-829.	1.0	3
78	Bright future for endoscopy: the new frontier of gastric cancer secondary prevention. Gut, 2020, 69, 1723-1724.	6.1	3
79	PTU-178...Clinical Utility Of Endofaster® In Patients On Chronic Ppi Therapy Undergoing Upper Gi Endoscopy. Gut, 2014, 63, A117.1-A117.	6.1	2
80	Assessment and monitoring of liver function by 13C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie, 2015, 53, 21-27.	0.2	2
81	Biopsy Sampling in Upper Gastrointestinal Endoscopy: A Survey from 10 Tertiary Referral Centres Across Europe. Digestive Diseases, 2021, 39, 179-189.	0.8	2
82	Myths and misconceptions in the management of Helicobacter pylori infection. Frontline Gastroenterology, 2022, 13, 245-253.	0.9	2
83	Epidemiology and clinical characterization of HCC in a tertiary center in eastern Germany.. Journal of Clinical Oncology, 2011, 29, e12010-e12010.	0.8	2
84	A Man With a Testicular Mass and a Colon Stenosis. Gastroenterology, 2011, 141, 37-405.	0.6	1
85	Transarterial chemoembolization (TACE) does have little impact on hepatic metabolic function in patients with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2011, 29, e14527-e14527.	0.8	1
86	Barrett's oesophagus: diagnosis, surveillance and treatment. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 444-450.	0.2	0
87	PTH-167...Clinico-pathological characteristics of patients under barrett's surveillance at a tertiary referral centre. Gut, 2015, 64, A482.1-A482.	6.1	0
88	Response to. European Journal of Gastroenterology and Hepatology, 2015, 27, 985-986.	0.8	0
89	Tu2054 Siewert Type Does Not Reflect Cancer Biology at the Gastro-Esophageal Junction. Gastroenterology, 2016, 150, S1011.	0.6	0
90	Gastric Cancer; Epidemiology and Diagnosis. , 2020, , 553-564.		0

#	ARTICLE	IF	CITATIONS
91	Progress in the treatment of cancer patients “ don’t forget the gut feeling!. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2020, 48-49, 101704.	1.0	0
92	Recent progress in the understanding of gastric cancer “ Do patients experience a benefit yet?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 50-51, 101740.	1.0	0
93	Association of a DNA damage response deficiency (DDR) assay with prognosis in resected esophageal and gastric adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 4026-4026.	0.8	0